Eli Lilly's pirtobrutinib qhia tau hais tias muaj txiaj ntsig zoo hauv CLL / SLL / MCL cov neeg mob uas tau ua tsis tiav covalent BTK inhibitor therapy!

Loxo Oncology, kev tshawb fawb txog oncology thiab kev loj hlob ntawm Eli Lilly, tsis ntev los no tshaj tawm lub hom phiaj tshuaj tiv thaiv kab mob pirtobrutinib (LOXO-305) rau kev kho mob ntawm chronic lymphocytic leukemia (CLL), me lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) Hloov kho. Cov ntaub ntawv kho mob los ntawm lub ntiaj teb Phase 1/2 BRUIN kev sim tshuaj. pirtobrutinib yog ib qho kev tshawb nrhiav, xaiv tau zoo, tsis yog-covalent, Bruton' s tyrosine kinase (BTK) inhibitor.

Cov ntaub ntawv tau qhia tag nrho cov lus teb (ORR) ntawm 68% hauv cov neeg mob CLL / SLL yav dhau los kho nrog BTK inhibitor, uas tau txhim kho mus rau 73% hauv cov neeg mob ua raws li 12 lub hlis lossis ntev dua, tsis hais txog BTK ORR ua ntej tau zoo ib yam txawm tias yog vim li cas. rau inhibitor discontinuation lossis BTK kev hloov pauv. Ntawm cov neeg mob MCL uas yav tas los tau txais BTK inhibitors, ORR yog 51%; ntawm MCL cov neeg mob uas tsis tau txais BTK inhibitor yav dhau los, ORR yog 82%.

BRUIN is the largest clinical trial to date to enroll patients with CLL/SLL who have previously received modern standard of care, including BTK and BCL2 inhibitors. In this real-world relapsed/refractory patient population, pirtobrutinib continued to demonstrate robust activity with a favorable safety profile on long-term treatment. With longer follow-up, evidence of durable disease control was observed in this previously heavily treated CLL/SLL population. There are currently no evidence-based treatment options for patients receiving covalent BTK and BCL2 inhibitors, and pirtobrutinib has the potential to provide a meaningful new therapy for these CLL/SLL patients as well as those who have previously received fewer regimens.

In MCL, the number of evaluable patients who had previously received BTK inhibitors has doubled since the last data analysis, and nearly the same response rate was observed. New treatment options following covalent BTK therapy represent an urgent unmet medical need, and the durable response rates observed with pirtobrutinib treatment demonstrate the drug's potential to provide significant clinical improvement in MCL patients receiving covalent BTK therapy.

Chemical structural formula of Pirtobrutinib (Duab qhov chaw: pubchem)

Raws li lub Xya Hli 16, 2021, tag nrho ntawm 618 tus neeg mob tau tso npe rau hauv txoj kev tshawb no, suav nrog 296 tus neeg mob CLL / SLL, 134 cov neeg mob uas muaj cov qog ntshav qog ntshav qog ntshav (MCL), thiab 188 cov neeg mob uas muaj lwm cov kab mob B-cell malignancies. Cov ntaub ntawv ua tau zoo yog ua raws li kev soj ntsuam cov lus teb. Cov neeg mob raug suav hais tias muaj txiaj ntsig rau kev ua tau zoo yog tias lawv muaj tsawg kawg yog ib qho kev ntsuam xyuas tom qab cov lus teb los yog txiav kev kho mob ua ntej thawj qhov kev ntsuam xyuas tom qab.